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Objective: Depression is more common among individuals with chronic physical illness than in the general
population. New treatments for severe and chronic inﬂammatory conditions which inhibit tumour necrosis
factor alpha (TNF-α), a pro-inﬂammatory cytokine, may be able to shed some light on the role of inﬂammatory
mediators in depression. This systematic review and meta-analysis of randomised controlled trials determined
the effects of TNF-α inhibitor therapy on depression and anxiety in people with chronic physical illness.
Methods: Seven databases were searched from inception to January 2014: AMED, Central, Cochrane Database of
Systematic Reviews, CINAHL, Embase, MEDLINE, and PsycINFO. Articles were screened for inclusion indepen-
dently by two reviewers. Data extraction and appraisal were conducted by one reviewer and checked by a
second. Random-effects meta-analyses were performed.
Results: Six randomised controlled trials (reported in seven articles) met eligibility criteria and were included in
the ﬁnal review. In total 2540 participants were enrolled across the trials, with participants presenting with
rheumatoid arthritis (n = 3 trials), psoriasis (n = 2) or ankylosing spondylitis (n = 1). Meta-analyses, using
standardised mean differences, showed evidence of small reductions in depression (−0.24; 95% CI−0.33 to
−0.14; p b 0.001), and anxiety (−0.17; 95% CI−0.31 to−0.02; p = 0.02).
Conclusion: TNF-α inhibitor therapy reduces depression in people with chronic disease though the effects are
small.Whilst this is consistent with inﬂammation contributing to the development of depression, further studies
investigating a more detailed timeline of changes in depression, inﬂammatory biomarkers and disease activity
status are required.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Depression is two to three times more common in people with
chronic physical illnesses than in the general population [1]. This is of
particular concern as depression is associated with a range of adverse
outcomes among people with chronic physical illnesses, including
increased mortality [2–4], increased morbidity [5,6], poorer health-
related quality of life [7–9], and increased healthcare use and costs
[10,11]. The causes of depression in the physically ill are complex and
multifactorial. General risk factors, such as being female, having a family
or personal history of depression, having markers of social deprivation,
a lack of social support and marked psychosocial stresses are known to
be predictive of depression [12]. Factors relating to the illness and itsxeter Medical School, St. Luke’'s
. This is an open access article undertreatment also inﬂuence who develops depression, such as negative be-
liefs about illness [13], the presence of pain [12,14], disability [15,16]
and unpleasant side-effects from treatment [17]. Understanding the
causes of depression is of central importance in the management of in-
dividuals with chronic physical illnesses as it offers the opportunity to:
i) identify those at greatest risk of additional illness burden due to de-
pression, ii) identify those at risk ofworsemedical outcomes and iii) po-
tentially reduce the risks of adverse medical outcomes, either by
treating depression or increasing the intensity of medical management.
Recently there has been growing interest in the roles of inﬂamma-
tion in contributing to the development of depression in people with
physical illness [18,19]. Depression is associated with an increase in
biomarkers of inﬂammation, including c-reactive protein (CRP), inter-
leukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor alpha
(TNF-α), in clinical and community populations [20–22]. Epidemiolog-
ical studies have demonstrated that depression is predicted by higher
levels of inﬂammatory mediators [23,24], though such prospectivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Study characteristics and summary of main depression and anxiety outcome data.
Author Location Population
(including prevalence of depression
& anxiety)
Intervention Depression
& anxiety
measure
Findings (Intervention vs Comparator)
Bae 2013
APPEAL
study
Multi (Hong Kong, India,
Malaysia, Philippines,
Taiwan, Korea and
Thailand)
300 adults with rheumatoid arthritis (who
showed inadequate response to oral MTX),
mean age 48 yrs
Baseline depression prevalence not reported
Open-label study.
ETN (25 mg 2/week) + MTX
(n = 197) vs DMARD +MTX
(N = 103) for 16 weeks
HADS Depression improvement:
7.62 to 5.42 (−28.7%) for ETN vs 7.85 to
6.56 (−16.4%) for DMARD, p = 0.016
Anxiety improvement:
29.1%(ETN) vs 18.5% (DMARD)
improvement, p = 0.026
Kekow
2010
COMET
study
Multi (Europe, Latin
America, Asia, Australia)
528 adults with early active rheumatoid
arthritis, mean age 51 yrs
Baseline depression: 47%
Baseline anxiety: 37%
Double blind study.
ETN (50 mg 1/week) + MTX
(n = 265) vs MTX (n = 263)
for 52 weeks
HADS Depression no signiﬁcant change:
6.82 to 4.39 (−2.43) for ETN vs 6.68 to
4.66 (−2.02) for MTX, Not Signiﬁcant (NS)
Anxiety no change:
−2.12 (ETN) vs−1.92 (MTX)
improvement, NS
Machado
2014
Multi (Argentina, Chile,
Columbia, Mexico,
Panama)
429 adults with rheumatoid arthritis
(who showed inadequate response
to MTX), mean age 48 yrs
Baseline depression prevalence not
reported
Open label study.
ETN (50 mg 1/week) + MTX
(n = 284) vs DMARD +MTX
(n = 145) for 24 weeks
HADS Depression improvement:
adjusted mean change:−2.8 (0.2) for
ETN vs−1.9 (0.3) for DMARD,
p = 0.0077
Anxiety no change:
−2.2(0.3) for ETN vs−1.7 (0.3) for
DMARD, p = 0.16
Menter
2010
Multi (USA and Canada) 97 adults with psoriasis, mean age 44 yrs
Baseline depression: 35%
Double blind study. ADM
(40 mg 1/week) (n = 45) vs
Placebo (n = 52) for 12
weeks
ZDS Depression improvement:
42.9 (12.4) to 36.2 (11.5) for ADAL vs
45.8 (14.0) to 44.2 (14.2) for placebo
Difference in change−6.0 (−9.5 to
−2.5), p = 0.001
(Improvement in ZDS correlated with
improvement in physical symptoms
(r = 0.5, p b 0.001), but not able to
assess which came ﬁrst)
Packham
2012
ASCEND
study a
Multi (centres across
the UK)
Subgroup of 48 adults with ankylosing
spondylitis in UK, mean age 41 yrs
Baseline depression prevalence
not reported
Double blind study. ETN
(50 mg 1/week) (n = 29)
vs SLZ
(n = 19) for 16 weeks
HADS Depression improvement:
effect size (ES) greater for ETN, n = 29,
(ES — 0.86) compared to SSZ, n = 15
(ES — 0.39), no statistics presented
Anxiety no change:
ES similar between 0.68 (ETN) vs 0.81
(SSZ), no statistics presented
Tyring
2006
Multi (USA and Canada) 620 adults with psoriasis, mean age 46 yrs
Baseline depression: 19% mild, 15%
moderate (BDI); 24% mild, 2% moderate
(HAM-D)
Double blind study. ETN
(25 mg 2/week)
(n = 311) vs Placebo
(n = 309) for 12 weeks
HAM-D
and BDI
Depression:
1) HAM-D Depression improvement
ETN vs Placebo, 1.5 vs 0.4, (CI
0.4–1.9, p = 0.0012), ES of 0.25
2) BDI Depression Improvement
ETN vs Placebo, 1.8, (CI 0.6–2.9,
p b 0.001), ES of 0.22.
(Changes in depression not strongly
correlated with objective clinical
measures.)
Van der
Heijde
2012
ASCEND
study a
Multi (Europe, Latin
America, Asia, Australia)
566 adults wit
ankylosing spondylitis, mean
age 41 yrs
Baseline depression prevalence
not reported
Double blind study.
ETN (50 mg 1/week)
(n = 379) vs SSZ (n = 187)
for 16 weeks
HADS Depression improvement:
Greater improvement in ETN vs SSZ:
−0.7 (3.0), p b 0.05
Anxiety improvement:
Greater improvement in ETN vs SSZ:
−0.6 (3.0), p b 0.05
Drug
ADM Adalimumab
DMARD Disease modifying anti rheumatic drug
ETN Etanercept
MTX Methotrexate
SSZ Sulphsalazine
Assessment tools
BDI Beck Depression Inventory
HADS Hospital Anxiety and Depression Scale
HAM-D Hamilton's Rating Scale for Depression
ZDS Zung's Self-rating Depression Scale
a Same study.
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pression predicting inﬂammation [22]. Controlled, experimental studiesin healthy volunteers, in which inﬂammation is triggered by the acute
administration of an endotoxin or attenuated vaccine, have
177R. Abbott et al. / Journal of Psychosomatic Research 79 (2015) 175–184demonstrated transient increases in the symptomsof depression associ-
ated with increases in IL-1 receptor antagonist (IL-1Ra), IL-6 and TNF-α
[25,26]. Furthermore, administration of Interferon alpha, which greatly
increases the level of inﬂammatory mediators, is associated with devel-
opment of major depression in up to one third of patients [27], which is
preventable in many by pre-treatment with antidepressants [28,29].
Whilst such observational studies and short-lived experimental studies
provide evidence that inﬂammatory mechanisms contribute to the
development of clinically signiﬁcant depression in people with chronic
physical illness, they fall short of proving the causal link.
The recent development of pharmacological agents which specif-
ically inhibit the inﬂammatory mediator TNF-α, a pro-inﬂammatory
cytokine, offer a new means of investigating the links between in-
ﬂammation and depression [30]. Administration of TNF-α inhibitors
have resulted in a reduction of depression-like and anxiety-like
symptoms in rodent models of depression [31,32]. In clinical studies,
TNF-α inhibitors have been shown to improve outcomes in a high
proportion of people with severe inﬂammatory disorders, who
have failed to respond to other treatments. Indeed, TNF-α inhibitors
have also been shown to improve depressive symptoms among peo-
ple with chronic inﬂammatory disorders [33], though this does not
always appear to be the case [34]. More recently, Arisoy and col-
leagues [35] have shown that patients with ankylosing spondylitis
who were treated with TNF-α inhibitors reported a signiﬁcant
decrease in depression which, importantly, was not associated with
changes in markers of clinical disease activity. They, and others
[36], have suggested that the improvements in depression but not
markers of clinical disease activity, provides support for an inﬂam-
matory mechanism underpinning the development and mainte-
nance of depression. Although the link between anxiety and
inﬂammation has been much less studied, with recent ﬁndings of
correlations between inﬂammatory markers and anxiety disorders
and increased inﬂammatory activation in patients with anxiety
disorders [37], anxiety was included as a secondary outcome of
interest.
The purpose of this systematic review therefore, was to determine
whether introduction of TNF-α inhibitor therapy in peoplewith chronic
physical illness reduces symptoms of depression and anxiety. As the
question of this review related to the association of inﬂammation with
depression and anxiety, we were interested in the effects across, rather
than within, populations with chronic illness. Further, the review
sought to explore the relationship between timing of change in depres-
sion and anxiety symptoms with change in either immunological or
clinical status.
Methods
The systematic review was conducted following the general princi-
ples published by the NHS Centre for Reviews and Dissemination [38]
and has been reported in accordance with the PRISMA statement [39].
The protocol was registered and published prior to the review
commencing with PROSPERO (http://www.crd.york.ac.uk/PROSPERO/)
in September 2013 (registration no. CRD 42013006068).
Types of studies
Only randomised controlled trials (RCTs) were considered eligible
for the purposes of this review.
Types of participants
Individuals with any chronic physical illness that received treat-
ment with a TNFα inhibitor as part of a randomised controlled trial.
The indications for TNF-α inhibitor therapymeant that we were like-
ly to only ﬁnd populations with inﬂammatory related conditions
such as rheumatoid arthritis, psoriasis, or ankylosing spondylitis.Studies which involved participants being treated for mental illness
alone were not eligible.
Types of interventions
The intervention of interest was treatment with TNF-α inhibi-
tors, compared against usual care (treatment with a non TNF-α inhibi-
tor) or control. At the time of the review, the available TNF-α
inhibitors were Etanercept, Inﬂiximab, Adalimumab, Certolizumab,
and Golimumab. Studies that simply compared two doses of TNF-α
inhibitors (with no control or usual care arm), or studies that assessed
attenuation/escalation of TNF-α inhibitors doses, in which both inter-
vention arms received at least one dose of TNF-α inhibitors were not
considered eligible for inclusion.
Outcome measures
The primary outcome of interest in this review was depression,
assessed using a validated psychological measure, such as the Hospital
Anxiety Depression Scale (HADS), and the Beck Depression Inventory
(BDI). A list of recognised measures of depression was agreed a priori
(CD and RA). Self-reported measures of mental health related quality
of life were not considered eligible. Secondary outcome measures of
interest were anxiety, assessed with a recognised psychological mea-
sure, and measures of inﬂammatory and clinical disease status (only
in relation to the timing of any changes in depression observed).
Search strategy
The search strategywas developed by an information specialist (AB)
in consultation with topic and methods experts (CD, BA, BW, JTC). The
strategy used a combination of MeSH terms and free text terms, includ-
ing terms for TNF-α inhibitor or agonist, including thenameddrugs, and
terms describing depression. An illustration of the exact search strategy
used on MEDLINE can be seen in Fig. 1. Seven databases were searched
from inception to January 2014: AMED, Central, Cochrane Database of
Systematic Reviews, CINAHL, Embase, MEDLINE, and PsycINFO. No
date or language restrictions were used. We also searched
ClinicalTrials.gov for recently completed and ongoing studies. Forward
and backward citation chasing of each included article was conducted.
Two reviewers (RA, with RW or AB) independently screened titles,
abstracts and full texts using the eligibility criteria. Discrepancies
were discussed and resolved by a third reviewer (RW or AB) where
necessary.
Risk of bias and study quality
The methodological quality of each paper was assessed using the
Cochrane ‘risk of bias’ tool [40]. The tool includes six key criteria against
which potential risk of bias is judged: adequacy of allocation sequence
generation; adequacy of allocation concealment; blinding of partici-
pants, personnel or outcome assessors; completeness of outcome
data; selectivity of outcome reporting, and other bias. In addition to
the Cochrane risk of bias tool, four additional aspects of quality relating
to reporting of eligibility criteria, similarity of baseline characteristics,
compliance with intervention and data collection tool validity were
assessed. Quality was assessed by one reviewer (RA, AB, or RW), with
judgements checked by a second (RW, RA, or AB). Any discrepancies
were discussed and resolved.
Data collection
Data on the study design, the setting, the population, the interven-
tion, the outcomes and results, and risk of bias were collected using a
standardised, piloted data extraction form. Data were extracted by one
of two reviewers (RA, AB) and fully checked by another (RA or RW).
Database: Ovid MEDLINE(R) <1946 to October Week 5 2013>
Search Strategy:
--------------------------------------------------------------------------------
1     antitnf*.tw. (30)
2     "anti tnf*".tw. (7674)
3     tnf*.tw. (123764)
4     "Tumour necrosis factor*".tw. (18084)
5     exp Tumor Necrosis Factor-alpha/ (101615)
6     Adalimumab.tw. (3783)
7     Humira.tw. (178)
8     Etanercept.tw. (4467)
9     Enbrel.tw. (207)
10     Infliximab.tw. (7247)
11     Remicade.tw. (216)
12     Certolizumab.tw. (442)
13     Pegol.tw. (322)
14     Golimumab.tw. (242)
15     Simponi.tw. (7)
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 (159371)
17     randomized controlled trial.pt. (389483)
18     controlled clinical trial.pt. (89863)
19     randomi#ed.ab. (349033)
20     placebo$.ab. (157253)
21     drug therapy.fs. (1765660)
22     randomly.ab. (199204)
23     trial.ab. (302100)
24     groups.ab. (1275059)
25     exp animals/ not humans.sh. (4058478)
26     17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (3304198)
27     26 not 25 (2814515)
28   exp Depression/ (76808)
29     depress*.tw. (302892)
30     depressive disorder/ or exp depressive disorder, major/ or exp dysthymic disorder/ (78451)
31     dysthym*.tw. (2575)
32     antidepress*.tw. (45785)
33     "anti depress*".tw. (1374)
34     28 or 29 or 30 or 31 or 32 or 33 (358122)
35     16 and 27 and 34 (445)
****************************************
Fig. 1. Example of search strategy used on Medline.
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Since our underlying question related to the association of inﬂam-
mation with depression and anxiety, rather than with speciﬁc illnesses
and depression/anxiety, populations receiving TNF-α inhibitor therapy
were grouped together, rather than analysed by speciﬁc conditions.
Randomeffectsmeta-analyseswere performedwherewe had sufﬁcient
data from RCTs for the effect of intervention on the outcome measures
of depression and anxiety. Poolingwas performed on the post interven-
tion outcomemeasurement. Aswe used a random-effectsmodel for the
meta-analyses, theweightings for each studywere determined not only
by the size of each study included, but also by the estimate of between-
study heterogeneity. All studies assessing depression, analysed changein outcome between baseline and post intervention. Across the six trials
therewere four different scales used to assess depression, and one study
[41] only reported an adjusted standardised effect size between inter-
ventions and control, Therefore, in all but one study [41], unadjusted
post-intervention summary data were used to calculate standardised
effect sizes (ES) between groups. In the case of the Tyring et al. study
[42], where two different scales were used to measure the same
outcome from the same population, we computed a single effect size
as the mean of the effect sizes of the two scales and a variance that
takes into account the correlation between the two scales [43]. As
some have queried the interpretability of standardised effect sizes
[44], we also performed a random effects meta-analysis on the non
standardised mean differences data for studies in which the same
179R. Abbott et al. / Journal of Psychosomatic Research 79 (2015) 175–184depression scale only had been used. Data for this analysis is report-
ed as the pooled mean difference with 95% conﬁdence intervals.
Anxiety was measured across the studies using the same assessment
tool; however, as only the adjusted standardised effect size between
groups was reported in one study [41], pooled effects are reported as
standardised effects sizes with 95% conﬁdence intervals. Heteroge-
neity across estimates was quantiﬁed using the I-squared statistic
and tested using the Q-statistic [45]. Synthesised results are present-
ed by outcome type. Effect sizes are expressed as small (0.2–0.5),
moderate (0.5–0.8) and large (N0.8) [46]. Where pooling was not
appropriate or possible, the ﬁndings have been summarised in narra-
tive form.
Data analysis was carried out using Stata [Stata Corporation. Stata
Statistical Software. Release 12.1. College Station,TX, 2011] and Review
Manager (RevMan) Version 5.2 software (http://ims.cochrane.org/
revman). Synthesised results are presented by outcome type. Effect
sizes are expressed as small (0.2–0.5), moderate (0.5–0.8) and large
(N0.8) [46].Where poolingwas not appropriate or possible, theﬁndings
have been summarised in narrative form.Fig. 2. PRISMA ﬂow diagram showingResults
The electronic searches found a total of 1351 results, 360 of which were duplicates,
leaving 991 titles and abstracts to screen. After double screening of each one, 28 full
texts were retrieved for closer examination. A total of seven articles (from six trials)
were included in theﬁnal review,with two identiﬁed from forward and backward citation
chasing. Reasons for exclusion at the full text stage can be seen in Fig. 2. The ASCEND trial
was reported in two articles: a UK group subset only [47], and the full multicentre study
[41]. Data from the full study were used for all analyses where possible.
Study characteristics
All included articles reported onmulti-centre randomised controlled trials conducted
acrossmore than one country (see Table 1.). Trial size ranged from 48 to 620 participants,
with ﬁve of the six trials having N300 participants [34,41,42,48,49]. In total, 2540 partici-
pants were enrolled across the six trials. Participants were those presentingwith rheuma-
toid arthritis (n=3 trials) [34,48,49], psoriasis (n=2) [42,50], and ankylosing spondylitis
(n= 1) [41,47]. Themean age of participants recruited ranged from 41 to 51 years, and all
trials were of mixed sex. All six trials were primarily safety and efﬁcacy studies (the main
clinical and safety ﬁndings being presented elsewhere) in participants with moderate to
severe chronic disease, with depression being assessed as a secondary outcome measure.
Only one study [42] reported excluding participants with psychiatric disease, and the
same study also reported the intention to withdraw any patients who became activelyidentiﬁcation of included studies.
180 R. Abbott et al. / Journal of Psychosomatic Research 79 (2015) 175–184suicidal during the trial. Three studies [34,42,50] reported prevalence of depression and
anxiety at baseline, and themood state in these populations were found to be representa-
tive of other studies of populations with chronic disease, ranging between 16–47% of par-
ticipants showing some degree of clinical depression and/or anxiety. None of the studies
proactively recruited participants with depression.
Intervention characteristics
All six trials excluded anyone that had previously received TNF-α inhibitor treatment.
The three trials for participants with rheumatoid arthritis all assessed the TNF-α inhibitor
etanercept. Etanercept was used in conjunction withmethotrexate and compared against
the standard disease modifying anti-rheumatic drug (DMARD) of choice plus methotrex-
ate in two open-label RCTS [48,49], and against methotrexate alone in the third double-
blind RCT [34]. Trial length ranged from 16 to 52 weeks. The two trials for participants
with psoriasis were both placebo controlled double-blind trials and assessed the effects
of adalimumab [50] and etanercept [42] respectively. Both trials were of 12 weeks
duration. The trial for those with ankylosing spondyitis was a 4 month long double blind
study, reported in two articles, comparing etanercept to sulphasalazine [41,47]. All sixCochrane risk of bias
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Fig. 3. Cochrane risk of bias ttrials found signiﬁcant clinical beneﬁt of TNF-α inhibitor treatment compared to compar-
ator treatment [34,42,48,49,51,52].
Psychological outcome measure
Depressionwas assessed as a secondary outcome in all six trials. Four of the trials used
the Hospital Anxiety and Depression Scale (HADS) [34,41,47–49], one used the Zung
Depression Scale (ZDS) [50] and one trial used two different scales: the Hamilton Rating
Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) [42]. Anxiety
was also assessed as a secondary outcome in four trials, with HADS as the assessment
tool [34,41,47–49].
Study quality (risk of bias)
A summary of the risk of bias is presented in Fig. 3. For a few trials, some of the
information for this, where referred to and available, was taken from the ‘parent’ primary
outcome paper [51–54] which described the trial methodology in more detail. Whilst all
six included articles were RCTS, the studies were not without issues relating to possibleOther bias
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able of included studies.
181R. Abbott et al. / Journal of Psychosomatic Research 79 (2015) 175–184bias. For the majority of studies, the methods of randomisation and selection of eligibility
criteria were well described. Four of the trials were double blind and for these studies,
there was little risk of bias with regard to blinding of participants and outcome assess-
ments. However, two open-label studies were susceptible to bias of outcome measure-
ment, but these limitations were recognised in both papers. For most of the studies,
outcome data were complete or missing data were accounted for adequately, however
none of the studies reported on compliance with the intervention. Data collection tools
for depression and anxiety were all valid and reliable. All articles were presenting data
that was secondary to the primary aim of the trial, and all articles included authors that
were either employed by a pharmaceutical company or had received monies from
pharmaceutical industry, though the degree towhich theywere involved in data interpre-
tation and analysis was not stated for any of the articles.
Effects on depression
Data from all six trials were included in the meta-analysis on the effects of treatment
on depression. TNF-α inhibitor therapywas found to have a signiﬁcant beneﬁcial effect on
depression across a variety of clinical populations in ﬁve of the six trials, showing small to
medium effects. Pooling the studies together, irrespective of the depression assessment
tool used, we found a small but statistically signiﬁcant effect size of−0.24 in favour of
the intervention group (95% CI:−0.33 to−0.14; p b 0.001). The heterogeneity between
studies (38%) was not statistically signiﬁcant (p = 0.15). The forest plot for this analysis
is shown in Fig. 4. Repeating the analysis to include only studies that reported non
standardised data utilising the same depression assessment tool, resulted in comparable
ﬁndings: the pooled effect of TNF-α inhibitor treatment on depression in people with
rheumatoid arthritis, as measured by HADS [34,48,49], resulted in an overall mean
difference in HADS of−0.65 (95%CI:−1.15 to−0.16, p = 0.009) in favour of the inter-
vention group; this equates to a pooled standardised mean difference of 0.16, in the
three studies included in this sub-analysis. There was 12% heterogeneity between the
three studies which was not statistically signiﬁcant (p = 0.32).
Two studies [42,50] assessed whether there was an association between change in
depression and change in clinical disease status. Menter et al. [50] found a signiﬁcant
correlation between the two, whilst Tyring et al. [42] found no strong correlation in the
two outcomes. Neither of the studies however assessed depression frequently enough to
determinewhether the changes indepression appeared prior to changes in clinical disease
status. None of the studies reported analysing depression in relation to inﬂammatory
markers.
Effects on anxiety
Four studies provided data suitable for meta-analysis. Three studies were in
populations with rheumatoid arthritis, and one in a population with ankylosing spon-
dylitis and all used HADS as the assessment tool. The pooled effect of TNF-α inhibitor
treatment on anxiety resulted in an overall standardised mean difference of−0.17 inNOTE: Weights are from random effects analysis
Overall  (I-squared = 38.4%, p = 0.150)
Van der Heijde 2012
Kekow 2010
Menter 2010
ID
Machado 2014
Bae 2013
Study
Tyring 2006
favours Intervention  
0-1.02
Fig. 4. Forest plot showing the results of the meta-analysis onfavour of the intervention group which was statistically signiﬁcant at 5% level of sig-
niﬁcance, 95% CI: −0.31 to−0.02; p = 0.02 (forest plot shown in Fig. 5). There was
61.7% heterogeneity between the four studies which was borderline statistically sig-
niﬁcant (p = 0.05).
Discussion
This is the ﬁrst systematic review andmeta-analysis of the effects of
TNF-α inhibitor treatment on depression and anxiety in people with
chronic inﬂammatory disease. Data from six randomised trials (report-
ed in seven articles), involving a total of 2540 participants with moder-
ate to severe chronic inﬂammatory disease, showed a small but
statistically signiﬁcant effect of TNF-α inhibitor treatment on reducing
depression. Although notmeasured in all studies, a signiﬁcant beneﬁcial
effect of intervention was also observed for anxiety. The association
between improvement of depression with improvement in inﬂamma-
tory conditionwas inconsistent, however; one study reported an associ-
ation between clinical improvement and improvement in depression,
whereas another study observed no association between the two.
None of the studies were able to determine whether the changes in
depression occurred independent of, or prior to, any changes inmarkers
of clinical disease activity.
The review followed best practice guidelines for systematic reviews
[38] and did not restrict by date or language, nor bywhether studies had
been published or not. Authors of papers who had published abstracts
only, were contacted for their data, if available. Only data from placebo
(or usual care) controlled RCTswere eligible for this review, to enable us
to draw inferences about the causal relationship between use of TNF-α
inhibitors and improvements in depression. We pooled study ﬁndings
using standardised mean differences, to enable us to combine ﬁndings
using differing measures of depression and anxiety, but also presented
ﬁndings for the majority of studies using the same measure using
weighted mean difference, to aid interpretation. Importantly, the effect
size of TNF-α inhibitor treatment on depression was comparable
irrespective of the meta-analytic approach taken.
With regard to potential weaknesses, this review included RCTs for
which the primary aim had to been to assess safety and efﬁcacy of-0.24 (-0.33, -0.14)
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Fig. 5. Forest plot showing the results of the meta-analysis on the effects of TNF-α inhibitor treatment on anxiety.
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studies were robust, the primary aims of the trials were not to establish
effects on psychological status, nor to relate this to clinical disease status
and inﬂammatory biomarkers. Whilst this may be interpreted as
meaning that less effort and rigour may have been invested in the
assessments of depression, all the measures used were well-validated.
Importantly, the self-rated assessments performed similarly to the
observer rated HAM-D measure of depression in the one trial that
used both forms of assessment [42], which suggests that reliance on
self-rated depressionmeasures in themajority of studies did not inﬂate
the observed effects of TNF-α inhibitors on depression. Also by focusing
on secondary outcomes of trials, it could be argued that our ﬁndings are
less likely to be inﬂuenced by publication or reporting bias. Another
possible limitation for this review is the small number of studies that
the review located. Although the trials were of reasonable size, and
data from more than 2500 participants were pooled, for example for
analysis of the effects of TNF-α inhibitor therapy on depression, this
does only represent six studies, and therefore the results need to be
interpreted with caution. A further consideration must be given to the
fact that whilst the study participants were similar on the grounds
that they were receiving TNF-α inhibitor therapy for an inﬂammatory
condition, there is likely to have been considerable variation in both
the disease states, and other factors impacting on depression and anxi-
ety of the participants within each trial, and across the trials of different
chronic diseases. This variability in the nature of the underlying disease
characteristics and associated factors is likely to have contributed to the
heterogeneity between individual trials. Some small reassurance is
given by the three studies that reported baseline mood state, which
were found to be representative of other studies of populations with
chronic disease.
We interpret our ﬁndings as indicating that treatment with TNF-α
inhibitors in people with chronic inﬂammatory conditions improves
depression and anxiety. The effects of TNF-α inhibitors on depression
were small, however, and whilst there is no established minimum
clinically important difference for the HADS depression scale, the
small effect observed would be below what most would consider to
be clinically signiﬁcant. Such a small effect could indicate that other,non-TNF-α mediated mechanisms were important determinants of
depression among the patients studied. However, a number of method-
ological characteristics of the included studies could also have inﬂu-
enced the size of observed effect. First, these small effects could be
attributable, at least in-part, to the fact that the included studies did
not speciﬁcally recruit patients with depression or anxiety (one study
even excluded people with signiﬁcant psychopathology). The preva-
lence of depression and anxiety (in the three studies where these
were reported) were between 16–47%, meaning that the majority of
patients were not depressed, thereby limiting the potential for antide-
pressant effects. Secondly, in the control arm of most of the included
trials, active anti-inﬂammatory drugs (treatment as usual) were used
which may have reduced the apparent effects of TNF-α inhibitors.
Effects in trials using placebo control were not systematically greater
than those that had used active treatment however, suggesting this is
unlikely to have inﬂuenced the ﬁndings of this review.
Other randomised studies of TNF-α inhibitor treatment in chronic
disease have reported effects on depression of greater magnitudes to
that found in this review. Studies which have randomised patients
with psoriasis to either paused or continuous etanercept treatment, or
varying doses of etanercept, found 25–30% improvement in HADS
depression scores, between a 1.5–2.0 decrease (compared to our mean
effect difference in our review of 0.65) [55,56]. Whist the intervention
groups in the RCTs in our present review also saw decreases in depres-
sion of similar magnitude (i.e. of between 1.0–3.0 in HADS depression
score), depression scores in the control groups in our included studies
were also found to improve, albeit by less, hence the lower overall
mean effect difference. Loftus, in their study randomising individuals
to different doses of adalimumab for Crohn's disease, found a signiﬁcant
reduction in depression (9 points on the ZDS), slightly higher than that
reported in the study by Menter et al., included within this review [57].
Of interest, the regimes used in these dosing studies were comparable
and/or higher to those used in the studies in this present review, how-
ever none of them observed greater responses with the higher doses.
Whilst these trials comparing different doses of the TNF-α inhibitors
were excluded by our a priori criteria, their ﬁndings are in agreement
with a small but signiﬁcant effect of TNF-α inhibitors on depression.
183R. Abbott et al. / Journal of Psychosomatic Research 79 (2015) 175–184Whilst our review provides evidences that treatment with TNF-α
inhibitors improves depression, it fails to indicate whether the mecha-
nisms of improving depression are directly mediated by a reduction in
TNF-α or whether the beneﬁts to depression are secondary to reduc-
tions in pain and disability associated with improvement in chronic
inﬂammatory condition. None of the included studies provided sufﬁ-
cient detail of the timing of changes in depression relative to the chang-
es in clinical disease status to determine whether improvements in
mood predate improvements in markers of clinical status. In the study
by Tyring et al. [42], there was a lack of a strong correlation between
the improvements in depression and in markers of clinical disease
status, which led the authors to conclude that treatment affected de-
pression directly (i.e. not secondary to improvements in clinical status).
Raison et al. [58] have recently considered the mechanism of effect
of TNF-α inhibitors on depression in the ﬁrst published RCT of TNF-α
inhibitor therapy (inﬂiximab) for individuals with treatment resistant
depression. They found that Inﬂiximab had no overall effect on depres-
sion in the sample as a whole. Whilst individuals with diagnosed auto-
immune disorders were excluded, the authors did ﬁnd reductions in
depression among subjects with higher baseline levels of inﬂammation
(hs-CRP N 5 mg/L). In addition to this, a case study of TNF-α inhibitor
therapy (inﬂiximab) for ﬁve individuals with late onset depressive
disorder, found no effect on depression in four individuals, but complete
disappearance of depressive symptoms in the only patient with a
comorbid inﬂammatory condition [59]. The ﬁndings of both of these
studies are consistent with the conclusion that TNF-α inhibitors
improve depression directly via inﬂammatory pathways, though both
fall short of proving this mechanism of effect.
Future research needs to advance the extant ﬁndings and start to
tease out the some of the unknown issues highlighted. For example,
does TNF-α inhibitor therapy beneﬁt certain subgroups of populations
with depression who present with elevated inﬂammatory biomarkers?
As such,might existing levels of TNF-α, or other inﬂammatory biomark-
er, in individuals with depression indicate who is likely to respond to
therapy? Furthermore, might there be other characteristics (biological,
psychological and social) that identify who are most likely to respond
to TNF-α inhibitor therapy? In terms of trying to understand the mech-
anism, there is still uncertainty about whether TNF-α inhibitors are
having a direct effect on depression or whether they are indirectly
improving depression by improving the underlying physical condition.
Trials that look at the timing of the depression response might shed
light on this and establish whether depression improves even when
physical health does not.Conclusion
In summary, TNF-α inhibitor therapy reduces depression and
anxiety in people with chronic disease. Whilst this is consistent with a
proposed inﬂammatory mechanism of depression, further studies are
require to establish the mechanism of effect, by investigating a more
detailed timeline of changes in depression, clinical markers of disease
activity status and inﬂammatory biomarkers, and the extent to which
improvements in depression correlate with improvements in clinical
and inﬂammatory status.Funding
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